A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors

Area of Science:

• Molecular Biology
• Medicinal Chemistry
• Oncology

Background:

• Receptor tyrosine kinases (RTKs) are crucial in cellular processes; their dysregulation is linked to diseases, particularly cancer.
• c-Kit, a type-III RTK, is implicated in various cancers, with mutant isoforms playing a significant role.
• Targeting c-Kit has shown promise in treating diverse cancers, including gastrointestinal stromal tumors, melanoma, and acute myeloid leukemia.

Purpose of the Study:

• To provide a comprehensive overview of c-Kit inhibitor discovery.
• To offer insights into the structural, signaling, and pharmacophoric aspects of c-Kit inhibitors.
• To guide the understanding of requirements for targeting c-Kit, focusing on selectivity and efficacy.

Main Methods:

• Compilation of existing literature on c-Kit inhibitors.
• Analysis of small-molecule heterocycles with reported c-Kit inhibitory activity.
• Review of pharmacophores, binding modes, and Structure-Activity Relationship (SAR) data.

Main Results:

• Detailed information on the structure and signaling pathways of c-Kit.
• Comprehensive analysis of pharmacophores, binding modes, and SAR for various c-Kit inhibitors.
• Identification of key factors contributing to the selectivity and efficacy of c-Kit targeting molecules.

Conclusions:

• This compilation serves as a valuable resource for understanding c-Kit inhibitor development.
• It provides a foundation for designing novel small-molecule inhibitors with improved selectivity and efficacy.
• The insights gained can accelerate the discovery of new targeted therapies for c-Kit-driven cancers.